Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04119024 |
|
Recruitment Status :
Recruiting
First Posted : October 8, 2019
Last Update Posted : April 28, 2022
|
Sponsor:
Jonsson Comprehensive Cancer Center
Collaborator:
City of Hope National Medical Center
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | October 1, 2024 |
| Estimated Study Completion Date : | October 1, 2025 |